Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 3;218(6):247-249.
doi: 10.5694/mja2.51880. Epub 2023 Mar 19.

Assessing preparedness for Alzheimer disease-modifying therapies in Australasian health care systems

Amy Brodtmann  1   2 , David Darby  1 , Carly Oboudiyat  3 , Colin J Mahoney  4 , Campbell Le Heron  5 , Peter K Panegyres  6 , Bruce Brew  7
Affiliations

Assessing preparedness for Alzheimer disease-modifying therapies in Australasian health care systems

Amy Brodtmann et al. Med J Aust. .
No abstract available

Keywords: Alzheimer disease; Dementia; Health personnel; Magnetic resonance imaging; Medical colleges; Neurodegenerative disorders.

PubMed Disclaimer

References

    1. Cavazzoni P. FDA's decision to approve new treatment for Alzheimer's disease [7 June 2021]. US Food and Drug Administration, 2021. https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-... (viewed Feb 2023).
    1. Budd Haeberlain S, Aisen P, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis 2022; 9: 197-210.
    1. Centers for Medicare and Medicaid Services. CMS finalizes Medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease [press release]. 7 Apr 2022. https://www.cms.gov/newsroom/press-releases/cms-finalizes-medicare-cover... (viewed Feb 2023).
    1. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med 2023; 388: 9-21.
    1. Tahami Monfared AA, Tafazzoli A, Chavan A, et al. The potential economic value of lecanemab in patients with early Alzheimer's disease using simulation modeling. Neurol Ther 2022; 11: 1285-1307.

Publication types

Associated data